Geiger-Gritsch, S. (2010): Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma. DSD: Horizon Scanning in Oncology 10.
|PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader|
Bendamustine for indolent NHL was assessed in three phase III trials, it was assessed in one phase III trial for patients with CLL and in one phase III clinical trial for multiple myeloma. In addition, six phase II trials of bendamustine in indolent NHL have been published and one phase II trial in CLL. No full publication of phase II trials in multiple myeloma was identified. Bendamustine can be seen as additional therapeutic option for some patients with indolent NHL. Although data indicating improvements in progression-free survival, it is difficult to conclusively judge the potential clinical benefit associated with bendamustine therapy in this indication. Second, based on the available evidence bendamustine can be seen as salvage therapy for patients with CLL. Regarding its use in multiple myeloma, bendamustine is recommended as salvage therapy due to limited evidence for bendamustine in this indication.
|Item Type:||DSD: Horizon Scanning in Oncology|
|Keywords:||Bendamustine, non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, multiple myeloma, oncology|
|Subjects:||WB Practice of medicine > WB 300-962 Therapeutics|
WH Hemic and lymphatic systems
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
|Series Name:||DSD: Horizon Scanning in Oncology 10|
|Deposited on:||14 Jul 2010 12:43|
|Last Modified:||14 Jul 2010 12:43|
Repository Staff Only: item control page